Author/Editor		Ferkolj, Ivo
Title		Novosti v terapiji KVČB
Translated title		Novel therapy of inflammatory bowel disease
Type		članek
Source		In: Križman I, editor. Interna medicina 2005: novosti in aktualnosti. Zbornik predavanj 2. kongres Združenja internistov SZD; 2005 okt 21-22; Ljubljana. Ljubljana: Slovensko zdravniško društvo, Združenje internistov,
Publication year		2005
Volume		str. 99-103
Language		slo
Abstract		The goal of an acute exacerbation of inflammatory bowel disease treatment is to induce remission and to maintain the remission. Therapy should begin with an assessment of disease localization, extent, severity and the response to prior treatments. Mild to moderately active disease should be treated with oral mesalazine 3 - 4,5 g daily, moderate to severe extensive colitis requires corticosteroid therapy. Distal disease can be treated either with topical mesalazine or topical corticosteroids or a combination of both. Severe to fuldminante colitis requires hospitalization and parenteral administration of corticosteroids. For the maintenance of remission of ulcerative colitis we use 5 - ASA compounds (mesalazin 2 - 3 g daily). The medications which are used to treat an acute exacerbation of Crohn's disease are: 5 ASA (3 - 4,5 g daily), antibiotics, gluccocorticoids and nutritional therapy. An orally controlled-release preparation of budesonide at a dose of 9 mg per day is a well-tolerated and effective therapy for active Crohns disease of the ileum and proximal colon. The development of novel, highly effective forms of therapy, such as infliximab, a monoclonal antibody against TNF alpha, has shown dramatic efficacy in the treatment of Crohns disease. The efficacy of mesalazin or other 5-ASA compounds in maintaining remission or prevention of postoperative recurrence for patients with Crohns disease is not as effective as in ulcerative colitis, we use mesalazin and azatioprin.
Descriptors		INFLAMMATORY BOWEL DISEASES PROCTOCOLITIS COLITIS, ULCERATIVE CROHN DISEASE